Phase 4 N=955 Prospective Trial of Tranexamic Acid in Cardiac Surgery
C.Surgical Procedure; Cardiac
Primary: Postoperative Blood Loss — 520; 490; 450 ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=150 Tranexamic Acid in Knee Joint Surgery
Osteoarthritis
Primary: Blood Loss — 1090; 716; 746 mls — p=<0.05
Phase 4 N=100 Tranexamic Acid in Surgery of Advanced Ovarian Cancer
Ovarian Cancer
Primary: Perioperative Bleeding Volume — 520; 730 milliliter — p=0.03
Phase 4 N=36 Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty
Femoral Neck Fractures
Primary: Number of Participants Who Needed Transfusions — 0; 5 Participants
Phase 4 N=84 Tranexamic Acid Dosing for Total Joint Arthroplasty
Arthropathy of Hip · Arthropathy of Knee
Primary: Change in Hemoglobin From Baseline to the First Post-operative Day (POD#1) — 2.15; 2.06; 2.11 g/dl
Phase 2 N=150 Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury
Hemorrhage · Shock · Wounds and Injuries
Primary: Change in HLA-DR Expression on Monocytes 72 Hours After Drug or Placebo Administration in Patient Groups (0g TXA (Placebo); 2g TXA; 4g TXA)." — 0.503; 0.509; 0.532 fold…
Phase 3 N=11,000 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean
Obstetrical Complications · Hemorrhage · Labor and Delivery
Primary: Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells — 201; 233 Participants — p=0.19
N/A N=260 Tranexamic Acid in Off-pump Coronary Surgery
Off Pump Coronary Artery Bypass Surgery
Primary: Number of Patients Required Allogenic Red Blood Cells Transfusion — 37; 54 participants — p=<0.05
Phase 3 N=330 American Trial Using Tranexamic Acid in Thrombocytopenia
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml
Phase 2 N=128 Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement
Hip Fractures · Intertrochanteric Fractures
Primary: Number of Subjects Transfused at Least 1 Unit of Packed Red Blood Cells — 17; 19 Participants
N/A N=76 TXA Study in Major Oncologic Surgery
Tranexamic Acid · Cancer · Major Surgery
Primary: Number of Participants Who Required Transfusion — 8; 5 Participants
Phase 3 N=616 TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
Hematologic Neoplasms · Hemorrhage · Hematopoietic Stem Cell Transplantation
Primary: The Proportion of Patients Who Die or Have Bleeding of WHO Grade 2 or Above by WHO Criteria During the First 30 Days From the First Dose of Trial Treatment, or Planned…
Phase 4 N=82 Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture
Femoral Fractures
Primary: Total Blood Loss — 370.7; 426.2 Milliliters (mL) — p=0.348
Phase 3 N=44 Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery
Coronary Artery Disease
Primary: Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood). — 632; 789 mL — p=0.0493
Phase 3 N=110 Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery
Post Partum Hemorrhage · Fibrinolysis; Hemorrhage · Blood Loss
Primary: Blood Volume Loss — 2274; 2407 milliliters
Phase 3 N=114 Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
Bleeding
Primary: Chest Tube Drainage — 200; 225; 375; 400 mL
Phase 4 N=138 Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?
Hip Fracture
Primary: Number of Participants Who Received a Hospitalization Transfusion — 18; 12 participants
Phase 4 N=14 Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study
Placenta Accreta · Postpartum Hemorrhage · Cesarean Section
Primary: Estimated Blood Loss (EBL) — 3116; 9420 cc
N/A N=25 Tranexamic Acid and Blood Clots in Knee Surgery
Venous Thrombosis
Primary: Deep Vein Thrombosis — 2 Participants
Phase 4 N=94 Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
Biliary Tract Surgical Procedures · Pancreaticoduodenectomy · Esophagectomy
Primary: Post-operative Blood Loss — 394.3; 494.3 milliliter (mL) — p=0.460
Phase 4 N=188 Topical Tranexamic Acid (TXA) in Joint Arthroplasty
Osteoarthritis · Hip Arthropathy · Shoulder Arthropathy
Primary: Post-operative Blood Loss — 1,062.88; 1,204.60; 933.92 mL
N/A N=88 Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid
Acetabulum Fractures
Primary: Intra-operative Blood Loss — 727.6; 560.1 Milliliters
Phase 3 N=52 Tranexamic Acid Dosing in Adult Spinal Deformity Surgery
Adult Spinal Deformity
Primary: Blood Loss — 2046; 1596 mL
Phase 4 N=177 Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
Scoliosis
Primary: Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge) — 1775; 2116; 1531 ml
Phase 3 N=288 A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding
Menorrhagia
Primary: Participants With Treatment-Emergent Adverse Events (AEs) — 218; 1; 3; 60 participants
Phase 2 N=101 Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
Acute Blood Loss Anemia · Osteoarthritis, Knee
Primary: Blood Loss — 1293.1; 940.2 mL
Phase 4 N=66 Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement
Osteoarthritis, Knee
Primary: Levels of Plasmin Anti-plasmin (PAP) - Marker of Fibrinolysis — 117.8; 1280.7; 1032; 1041.2 ug/L
N/A N=42 Tranexamic Acid for The Treatment of Gastrointestinal Bleeding
Gastrointestinal Bleeding
Primary: Re-bleeding — 6; 7 Participants
Phase 3 N=903 Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)
Traumatic Hemorrhage
Primary: 30 Day Mortality — 36; 45 Participants